SRPX and pachyonychia congenita: In PC, lower expression of SRPX was shown to correlate with poorer recurrence-free survival in patients and significantly lower expression of SRPX in high-risk Gleason scores of eight tumors compared to low- or intermediate-risk tumors was noted (Kamdar et al., 2019).